The COVID-19 pandemic negatively affected the overall sales of most of the companies Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents. However, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement.
The increasing burden of UTIs, diabetes, and kidney & liver diseases; rising geriatric population and the subsequent increase in age-associated diseases and increasing adoption of POC diagnostic tests are factors supporting the growth of this market. Growth opportunities in emerging economies provide lucrative opportunities for the players operating in the urinalysis market.
COVID-19 patients who did not develop an AKI, but who had blood and/or protein in their urine, should be monitored since they are at increased risk of developing chronic- and end-stage kidney disease. With the COVID-19 pandemic, in addition to the development of vaccines and therapeutic drugs, there is a growing call for the development of more precise and simple testing technologies and the expansion of testing structures.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153479294
Based on the test type, the urinalysis market has been segmented into pregnancy & fertility tests, biochemical urinalysis and sediment urinalysis. In 2020, the sediment urinalysis segment accounted for the highest CAGR. This can be primarily attributed to the increasing adoption of automated devices for sediment analysis.
Based on application, the urinalysis market is segmented into disease screening and pregnancy & fertility. In 2020, the disease screening segment accounted for the largest share of this market. Factors such as the increasing incidence of UTIs, diabetes, liver diseases and kidney ailments worldwide are driving the growth of this market.
Due to rapid growth in the senior population, the prevalence of age-associated diseases such as diabetes, liver, and kidney diseases are expected to increase significantly. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for tests such as creatinine, albumin, glucose, ketones, and bilirubin, etc.
In addition to the factors mentioned above, the Asia Pacific has emerged as an adaptive and business-friendly hub due to relatively less stringent regulations and data requirements. Moreover, as markets in the US and Europe are maturing, most players are shifting their focus to emerging markets.
The urinalysis market is segmented into five regions, namely, North America, Europe, Asia Pacific, and Rest of the World. In 2020, North America accounted for the largest share of the urinalysis market. The large share of this region can be attributed to growing geriatric population, implementation of favorable government initiatives, increasing healthcare expenditure, improved healthcare infrastructure, and the availability of technologically advanced instruments.
The major players operating in this market are Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Cardinal Health, Inc. (US), Abbott Laboratories (US), Danaher Corporation (US), Sysmex Corporation (Japan), Quidel Corporation (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), EKF Diagnostics (UK), Thermo Fisher Scientific Inc. (US), ARKRAY, Inc. (Japan).